Skip to main content

Table 2 Clinical outcomes (means ± standard deviation) of the IFN B 1B and NTZ group at the study time points

From: Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta

 

IFN B 1B Group

*p value

NTZ group

*p value

**p values

Behavioural assessment

t0 (SD)

t1 (SD)

t2 (SD)

t1vs t0

t2 vs t0

t2 vs t1

Time trend

t0 (SD)

t1 (SD)

t2 (SD)

t1 vs t0

t2 vs t0

t2 vs t1

Time trend

 

PASAT

44.7 (6.9)

45.1 (7.8)

49.1 (8.3)

1

0.3

-

0.2

42.0 (11.1)

45.0 (9.6)

47.5 (8.3)

0.8

0.1

-

0.1

0.8

FSMC

59.4 (17.7)

62.9 (17.6)

68.9 (12.3)

0.7

0.2

-

0.08

55.5 (19.1)

49.8 (16.5)

53.1 (13.9)

0.5

1

-

0.4

0.9

FAMS

122.4 (26.9)

116.9 (32.1)

109.2 (25.3)

1

0.2

-

0.2

133.3 (21.5)

132.7 (17.4)

133.7 (15.4)

1

1

-

0.9

0.2

EQ-VAS

64.3 (13.5)

59.2 (12.8)

59.8 (11.3)

0.9

1

-

0.5

78.5 (8.9)

71.2 (16.8)

77.3 (9.8)

0.3

1

-

0.2

0.6

TS

-

80.0 (11.1)

78.6 (10.2)

-

-

0.4

0.4

-

96.0 (6.9)

93.0 (7.3)

-

-

0.1

0.1

0.6

Adherence

-

91.7 (7.33)

90.6 (5.7)

-

-

0.6

0.6

-

100 (.00)

99.2 (2.5)

-

-

0.3

0.3

0.9

  1. *p = longitudinal generalized linear models; **p = group x time interaction.
  2. Abbreviation: NTZ natalizumab; IFN B 1B interferon; EDSS expanded disability status scale; PASAT 3” paced auditory serial addition test 3 sec.; FSMC fatigue scale for motor and cognition functions; FAMS functional assessment of multiple sclerosis; EQ-VAS euroQuol visual analogue; TS treatment satisfaction SD standard deviation.